

WY P&T Committee Meeting Minutes
Thursday, February 13, 2020
Cheyenne, WY
10 a.m – 1 p.m.

Members present: Alissa Aylward, Melinda Carroll, Paul Johnson, Scott Johnston, Kristen Lovas, Robert Monger, Chris Mosier, Scot Schmidt

Ex-officio: Cori Cooper, Melissa Hunter

Excused: Hoo Fang Choo, Joseph Horam, Garry Needham, Patrick Yost

Guests: Donna Artery, Melissa Eames, Sara Howe (CHC), Amy Stockton (CHC), Paul Williams (Tricida), Jenna Gianninoto (Abbvie), Joe Ferroli (Takeda), Roy Lindfield (Sunovion), Jane Stephen (Amgen)

Dr. Monger called the meeting to order at 10:00 a.m.

Introductions were made. Aimee was pleased to introduce the new PA member, Alissa Aylward.

Approval of Minutes

The minutes of the November 14, 2019 meeting were approved.

Department of Health

A. Pharmacy Program Manager Report: Cori introduced Jan Stall, the Provider and Benefit Management Administrator. The Department is currently working with a system integrator who will integrate the PBMS with the other claims systems and create a data warehouse. The Provider Enrollment system will go live in July. There are a few legislative bills of interest regarding access to the PDMP, drug importation studies, and pharmacists prescribing contraceptives. Medicaid expansion was introduced and promptly killed. Another bill is expected.

The drug importation bills are to study the feasibility and potential cost savings. HHS and FDA have provided guidance on pathways for states to import drugs. Biologics and injectables are excluded. The state would have to act as a wholesaler for pharmacies. Several states have passed bills allowing drug importation and concept papers are currently being reviewed by CMS. There is currently no federal rule.

B. Medical Director Report: None

C. DUR Manager Report: None

Old Business:

A. None

New Business

A. PA Criteria

1. Review existing criteria

- i. The Synagis label was updated to describe the continued dosing of infants following RSV infection. The Department of Health will allow requests as they come in and we will table until the May meeting while Aimee follows up with Dr. Horam.

2. New Drugs

- i. Trikafta is a new medication for Cystic Fibrosis. There was a motion, second and all were in favor of limiting to indication. Dr. Johnston asked Aimee to follow up on studies completed but not published.

- ii. Secuado is a new transdermal formulation of asenapine. The Committee agreed that there is no evidence of a difference in efficacy or safety compared to existing agents. Secuado was referred to the Department of Health for cost analysis and PDL placement.

- iii. Talicia is a new antibiotic/proton pump inhibitor combination for *H. pylori* infection. The Committee saw no evidence of a difference in safety or efficacy compared to existing agents. Talicia was referred to the Department of Health for cost analysis. Aimee will follow up with Dr. Choo regarding local sensitivity information.

3. Determine need for criteria

- i. Data regarding the off-label use of calcitonin for pain was reviewed. Calcitonin has a warning regarding risk of malignancy. One patient on Wyoming Medicaid appears to be using it for non-osteoporosis related pain. Aimee will follow up with the prescriber regarding this use. A full review of osteoporosis agents will be done in May.

Other

There being no further business, the open portion of the meeting was adjourned at 10:35 am and the Committee met in closed session.

Respectfully Submitted,

Aimee Lewis
WYDUR Manager